Archives
-
Birinapant (TL32711) for CRC Apoptosis Workflows
2026-09-11
Birinapant (TL32711) converts IAP biology into a practical probe for apoptosis induction in cancer cells, TNF signaling, and TRAIL sensitization. This workflow connects IAP antagonism with MDM1–TP53 chemoradiotherapy research while clearly separating established evidence from assay-development recommendations.
-
Imatinib (STI571) in Kinase Assay Workflows
2026-09-10
Imatinib (STI571) provides a controlled way to interrogate Abl, PDGF receptor, and c-Kit signaling in cellular and biochemical models. This guide combines practical inhibitor workflows with a spatial-metabolomics extension inspired by porous graphene LDI-MSI, helping researchers connect phosphorylation changes with tissue-level metabolic response.
-
Digestive Metabolomics of Withania somnifera Extracts
2026-09-10
The 2026 Journal of Agricultural and Food Chemistry study combines simulated gastrointestinal digestion, LC–MS/MS profiling, untargeted metabolomics, and molecular networking to examine how Withania somnifera extract constituents change before absorption. Withaferin A and withanoside IV were transformation-prone, whereas withanolide A was comparatively stable, demonstrating that digestive behavior depends on both compound identity and plant matrix.
-
SepM Mutations Rewire S. mutans Competition
2026-09-09
Liu et al. linked recurrent sepM missense mutations in clinical Streptococcus mutans isolates with stronger inhibition of S. gordonii, then connected those variants to altered SepM–CSP-21 binding and ComDE signaling. The study provides a useful genotype-to-phenotype framework for investigating bacterial competition in cariogenic biofilms, while also highlighting the importance of pH-dependent biochemical validation.
-
Nanoparticle RNAi Delivery in Bemisia tabaci
2026-09-09
The 2026 study developed a C60/alkylpolyglucoside nanocarrier system to improve dsRNA delivery against the Bemisia tabaci btCHS and btG6PI genes. Compared with naked dsRNA, the formulation produced stronger gene suppression and lower whitefly survival, supporting nanocarrier-assisted RNAi as a promising but still experimentally bounded pest-management strategy.
-
Perphenazine Beyond Dopamine: A Translational Bridge
2026-09-08
Perphenazine is best known as a dopamine D2 receptor antagonist, but its broader receptor profile and phenothiazine biology make it a useful translational research probe. This article connects neuropharmacology, mitochondria-mediated cell death induction, opioid tolerance suppression, and host-directed antibacterial research while distinguishing published findings from forward-looking workflow recommendations.
-
hiPSC Intestinal Organoids for Pharmacokinetic Studies
2026-09-08
A 2025 study established a direct 3D cluster-culture strategy for generating expandable, cryopreservable intestinal organoids from human induced pluripotent stem cells. The resulting organoids produced intestinal epithelial cells with enterocyte-associated metabolic enzyme and transporter activities, creating a more human-relevant platform for oral drug absorption and metabolism studies.
-
Flumequine: From Topoisomerase II to Translation
2026-09-07
Flumequine can serve as more than a catalog reagent: it is a mechanistic probe for connecting DNA topoisomerase II modulation with replication stress, DNA damage responses, and interpretable in vitro drug phenotypes. This translational guide explains how to design assays that distinguish target inhibition from growth arrest and cell killing.
-
(-)-JQ1: A Rigorous Control for BET Assays
2026-09-07
(-)-JQ1 is the inactive JQ1 stereoisomer that helps separate BET-dependent biology from vehicle, handling, and nonspecific treatment effects. This guide translates its use into practical workflows for epigenetics research, BRD4-dependent cell line studies, and HPV-associated cancer biology research.
-
Mianserin HCl in a 14-Day Placebo-Controlled Trial
2026-09-05
This double-blind inpatient study established that mianserin produced measurable antidepressant improvement beyond placebo over 14 days, while also demonstrating a rapid sleep benefit. Its placebo-controlled design, repeated mood assessments, and explicit separation of sedative and antidepressant effects remain useful for interpreting mianserin in psychiatric disorder research.
-
Arrb2, 6-ketoLCA, and Hepatic IRI
2026-09-04
The reference study identifies hepatocyte Arrb2 as a regulator of hepatic ischemia–reperfusion injury, linking its expression to increased 6-ketoLCA, M2 macrophage polarization, and reduced tissue damage. Its multi-level design, combining transplant-related clinical samples, a mouse ischemia–reperfusion model, primary-cell hypoxia–reoxygenation experiments, and metabolite analysis, provides a useful framework for studying hepatocyte–immune communication.
-
5-Azacytidine Workflow for DNA Demethylation
2026-09-04
Build reproducible 5-Azacytidine experiments around dose-time mapping, methylation readouts, and viability controls rather than relying on a single endpoint. This practical guide connects HNF4A silencing research with cancer-model workflows, including leukemia, gastric cancer, and multiple myeloma applications.
-
tFUS, Nespas, and SHP2 in Post-Stroke Neuroinflammation
2026-09-03
The reference study links low-intensity transcranial focused ultrasound stimulation with reduced post-stroke NLRP3 neuroinflammation through the Nespas/miR-383-3p/SHP2 axis. Its rat and microglial-cell experiments provide a mechanistic framework for studying how neuromodulation may alter inflammatory signaling, while also identifying SHP2 as a testable molecular mediator rather than a merely associated marker.
-
(+)-Bicuculline: GABAA Workflow Guide
2026-09-03
This practical guide explains how to prepare, control, and interpret (+)-Bicuculline as a GABAA receptor antagonist for studies of inhibitory neurotransmission and neuronal signaling. It is intended for controlled neuroscience research workflows only and should not be used for diagnostic, clinical, or therapeutic purposes.
-
H62 Dual Tubulin–DNMT Inhibition in Leukemia
2026-09-02
The reference study identifies H62, a letermovir derivative, as a leukemia-active compound that simultaneously disrupts β-tubulin function and DNMT1 activity. Its combined effects on mitotic progression, erythroid differentiation, apoptosis, reactive oxygen species, and gene regulation provide a mechanistic rationale for further development in erythroleukemia and related myelogenous leukemias.